Payment overview · 2025
General Payments
$911.73
15 reported records · 7 companies
Healthcare provider profile · identity verified
Michelle S Schecter, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant|Medical · BROOKLYN, NY · NPI 1508204165
Verified facts
What the public records show
CMS Open Payments records show Michelle S Schecter, PA received $911.73 in general payments during 2025 across 15 reported records.
Lilly USA, LLC accounted for 41.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 589 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 589 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $375.00 | 41.1% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$158.61 | 17.4% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $149.21 | 16.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $138.05 | 15.1% | 3 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $41.05 | 4.5% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $28.93 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.88 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $911.73 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $149.21 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $138.05 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $110.56 | 2 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $41.05 | 1 | 2025 |
Source payment records
|
|||||
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $28.93 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 589 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 84 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
589 | 140 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
100 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
589 | 140 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 940 | 308 |
| Metoprolol Succinate | Metoprolol Succinate | 758 | 257 |
| Amlodipine Besylate | Amlodipine Besylate | 636 | 211 |
| Losartan Potassium | Losartan Potassium | 610 | 199 |
| Eliquis | Apixaban | 589 | 140 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 507 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 451 | 145 |
| Clopidogrel | Clopidogrel Bisulfate | 340 | 116 |
| Metformin Hcl | Metformin Hcl | 338 | 114 |
| Simvastatin | Simvastatin | 338 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 267 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 78 |
| Furosemide | Furosemide | 240 | 77 |
| Carvedilol | Carvedilol | 231 | 81 |
| Omeprazole | Omeprazole | 221 | 65 |
| Xarelto | Rivaroxaban | 220 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 216 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 204 | 65 |
| Lisinopril | Lisinopril | 178 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 60 |
| Alprazolam | Alprazolam | 170 | 54 |
| Gabapentin | Gabapentin | 130 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 44 |
| Famotidine | Famotidine | 118 | 39 |
| Entresto | Sacubitril/Valsartan | 114 | 31 |
| Synthroid | Levothyroxine Sodium | 108 | 39 |
| Atenolol | Atenolol | 107 | 35 |
| Valsartan | Valsartan | 105 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 32 |
| Allopurinol | Allopurinol | 101 | 33 |
| Mounjaro | Tirzepatide | 100 | 26 |
| Tramadol Hcl | Tramadol Hcl | 95 | 21 |
| Potassium Chloride | Potassium Chloride | 94 | 32 |
| Trulicity | Dulaglutide | 93 | 18 |
| Ozempic | Semaglutide | 86 | 26 |
| Ranolazine Er | Ranolazine | 86 | 25 |
| Januvia | Sitagliptin Phosphate | 85 | 19 |
| Jardiance | Empagliflozin | 84 | 22 |
| Ezetimibe | Ezetimibe | 80 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 17 |
| Clonidine Hcl | Clonidine Hcl | 76 | 16 |
| Enalapril Maleate | Enalapril Maleate | 76 | 26 |
| Torsemide | Torsemide | 74 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 26 |
| Montelukast Sodium | Montelukast Sodium | 68 | 22 |
| Spironolactone | Spironolactone | 62 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 24 |
| Donepezil Hcl | Donepezil Hcl | 60 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 16 |
| Farxiga | Dapagliflozin Propanediol | 58 | 15 |
| Finasteride | Finasteride | 58 | 20 |
| Diazepam | Diazepam | 57 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 20 |
| Lorazepam | Lorazepam | 51 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 11 |
| Glimepiride | Glimepiride | 48 | 16 |
| Labetalol Hcl | Labetalol Hcl | 46 | 13 |
| Repatha Sureclick | Evolocumab | 45 | suppressed |
| Nifedipine Er | Nifedipine | 44 | 13 |
| Irbesartan | Irbesartan | 43 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 13 |
| Glipizide Er | Glipizide | 42 | 12 |
| Warfarin Sodium | Warfarin Sodium | 42 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 40 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 12 |
| Clonazepam | Clonazepam | 39 | 11 |
| Ramipril | Ramipril | 39 | 16 |
| Sertraline Hcl | Sertraline Hcl | 39 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | 15 |
| Brilinta | Ticagrelor | 38 | suppressed |
| Telmisartan | Telmisartan | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 36 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | suppressed |
| Folic Acid | Folic Acid | 35 | 14 |
| Digoxin | Digoxin | 33 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 32 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 15 |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | 11 |
| Bumetanide | Bumetanide | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | 11 |
| Colchicine | Colchicine | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Trulance | Plecanatide | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 16 | suppressed |
| Dofetilide | Dofetilide | 16 | suppressed |
| Levoxyl | Levothyroxine Sodium | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verquvo | Vericiguat | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Gralise | Gabapentin | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $911.73 · 15 records | Lilly USA, LLC | AMVIA EDGE, CAMZYOS, ELIQUIS, JARDIANCE, Kcentra, LINQ II, MICRA, MOUNJARO, NURTEC ODT, PAXLOVID, SYMPLICITY G3, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error